ArticleBMC cancer2025
Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human biomarker navigator.iMeta · 2026Review
- Baseline 18F-FDG PET/CT metabolic parameters and systemic inflammatory markers in advanced NSCLC treated with first-line immunotherapy: an exploratory retrospective analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study was to investigate the prognostic significance of parameters derived from ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line treatment with immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy, focusing on both primary tumors and metastatic sites located in the torso.
methodsThis retrospective study analyzed 70 patients diagnosed with stage III or IV NSCLC who underwent FDG PET/computed tomography (CT) prior to initiating first-line treatment with ICI-based combination therapy. Key metabolic metrics-including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG)-were quantified across all detectable lesions within the torso. Associations between these PET-derived parameters and clinical outcomes, including progression-free survival (PFS) and overall survival (OS), were examined using Kaplan-Meier survival estimates and Cox proportional hazards regression.
resultsMTV-torso and TLG-torso were significantly higher in patients with poor Eastern Cooperative Oncology Group performance status (PS ≥ 2). In univariate analyses, PS, MTV-torso, and TLG-torso were significantly associated with both PFS and OS. In multivariate analyses, PS and MTV-torso remained independent predictors of both outcomes. Patients with lower MTV-torso (< 225.81) had significantly higher mean PFS (582.3 vs. 154.5 days, P < 0.001) and OS (1,047.6 vs. 291.4 days, P < 0.001). SUVmax-torso was not significantly associated with survival.
conclusionsAmong the FDG PET-based volumetric indices, MTV-torso emerged as an independent predictor of both PFS and OS in patients with advanced NSCLC undergoing first-line treatment with ICI and platinum-based chemotherapy. These findings support the use of torso-based metabolic tumor burden assessment as a valuable tool for prognostic stratification in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.